Table 4.
All-cause ESKD-associated variants at P < 5 × 10–6 in baseline model
| Lead variant | CHR | POS | Locus | Effect/other alleles | Info | Stage 2 (3432 T2D-ESKD cases vs. 6977 non-diabetic non-nephropathy controls) | Stage 4 (1910 non-diabetic ESKD cases vs. 908 non-diabetic non-nephropathy controls) | Stage 5: Meta-analysis (5342 all-cause ESKD cases vs. 6977 non-diabetic non-nephropathy controls) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EAF | OR (95% CI) | P | EAF | OR (95% CI) | P | EAF | OR (95% CI) | P | HetP | ||||||
| rs76971802 | 3 | 188607071 | LPP | T/C | 0.95 | 0.087 | 1.35 (1.19,1.54) | 8.66E−06 | 0.084 | 1.42 (1.08,1.87) | 0.013 | 0.087 | 1.35 (1.2,1.52) | 1.36E−06 | 0.86 |
| rs5863506 | 4 | 162909217 | FSTL5 | TA/T | 0.96 | 0.33 | 1.22 (1.12,1.32) | 1.64E−06 | 0.33 | 1.19 (1.01,1.40) | 0.033 | 0.33 | 1.21 (1.12,1.30) | 4.57E−07 | 0.87 |
| rs141746998 | 8 | 54310938 | OPRK1/ATP6V1H | CAT/C | 0.94 | 0.031 | 0.62 (0.5,0.76) | 9.40E−06 | 0.034 | 0.61 (0.39,0.93) | 0.022 | 0.031 | 0.61 (0.5,0.75) | 1.44E−06 | 0.96 |
| rs11997465 | 8 | 110891977 | SYBU/KCNV1 | C/G | 0.99 | 0.28 | 1.22 (1.12,1.33) | 3.21E−06 | 0.28 | 1.21 (1.02,1.43) | 0.026 | 0.28 | 1.22 (1.13,1.31) | 6.72E−07 | 0.65 |
| rs77113398 | 13 | 107103906 | EFNB2 | A/G | 0.93 | 0.023 | 1.94 (1.52,2.47) | 1.25E−07 | 0.021 | 1.87 (1.08,3.24) | 0.025 | 0.023 | 1.94 (1.55,2.43) | 9.84E−09 | 0.96 |
| rs9622363 | 22 | 36656555 | APOL1 | A/G | 0.95 | 0.45 | 0.77 (0.72,0.84) | 1.42E−10 | 0.35 | 0.42 (0.36,0.48) | 4.32E−29 | 0.43 | 0.68 (0.64,0.73) | 1.96E−25 | 1.14E−09 |
Baseline model: adjusted for age, sex, and PC1; APOL1 risk genotype carriers were included
Abbreviations: T2D type 2 diabetes, ESKD end-stage kidney disease, CHR chromosome, POS position, EAF effect allele frequency, OR odds ratio, CI confidence interval, P, P value, Info average imputation quality, HetP heterogeneity P value